Loading... Please wait... Loading... Please wait...
ESTIMATED
04/10/2024
04/10/2024
(AS OF MARCH 31)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 3 | -$0.78 | -$0.78 | -$0.78 |
| Q2 2024 | 9 | -$0.75 | -$0.45 | -$0.63 |
| Q3 2024 | 7 | -$0.70 | -$0.70 | -$0.70 |
| Q4 2024 | 3 | -$0.73 | -$0.73 | -$0.73 |
| Q1 2025 | 4 | -$0.76 | -$0.76 | -$0.76 |
| Q2 2025 | 6 | -$0.77 | -$0.77 | -$0.77 |
| Q3 2025 | 4 | -$0.77 | -$0.77 | -$0.77 |
| Q4 2025 | 4 | -$0.78 | -$0.78 | -$0.78 |
Nurix Therapeutics, Inc. last posted its earnings results on Wednesday, April 10th, 2024. The company reported $-0.76 earnings per share for the quarter, topping analysts' consensus estimates of $-0.8 by $0.04. The company had revenue of 16.59 M for the quarter and had revenue of 76.99 M for the year. Nurix Therapeutics, Inc. has generated $-3 earnings per share over the last year ($-2.65 diluted earnings per share) and currently has a price-to-earnings ratio of -7.51. Nurix Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, July 11th, 2024 based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 04/10/2024 | Q1 2024 | -$0.80 | -$0.76 | 0.04 | $17.13 M | $16.59 M | 02/15/2024 | Q4 2023 | -$0.51 | -$0.77 | -0.26 | $15.16 M | 10/12/2023 | Q3 2023 | -$0.69 | -$0.68 | 0.01 | $18.47 M | 07/13/2023 | Q2 2023 | -$0.63 | -$0.40 | 0.23 | $30.68 M | 04/13/2023 | Q1 2023 | -$0.90 | -$0.65 | 0.25 | $12.69 M | 02/09/2023 | Q4 2022 | -$0.68 | -$0.77 | -0.09 | $6.78 M | 10/06/2022 | Q3 2022 | -$0.99 | -$0.88 | 0.11 | $10.79 M | 07/07/2022 | Q2 2022 | -$1.00 | -$1.00 | 0 | $11.43 M | 04/08/2022 | Q1 2022 | -$0.95 | $9.62 M | 01/28/2022 | Q4 2021 | -$0.85 | $13.19 M | $7.40 M | 10/14/2021 | Q3 2021 | -$0.63 | -$0.65 | -0.02 | $10.25 M | 07/13/2021 | Q2 2021 | -$0.54 | -$0.60 | -0.06 | $7.09 M | 04/13/2021 | Q1 2021 | -$0.46 | -$0.63 | -0.17 | $5.01 M | 02/16/2021 | Q4 2020 | -$0.54 | -$0.51 | 0.03 | $3.95 M | $6.69 M | 10/14/2020 | Q3 2020 | -$0.41 | -$1.09 | -0.68 | $4.09 M | 05/30/2020 | Q2 2020 | $0.22 | $4.18 M | 02/28/2020 | Q1 2020 | -$0.60 | $2.86 M | 11/29/2019 | Q4 2019 | -$0.65 | $1.86 M | 08/30/2019 | Q3 2019 | -$0.12 | $10.58 M |
|---|
A. Nurix Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, July 11th, 2024 based off last year's report dates.
A. In the previous quarter, Nurix Therapeutics, Inc. (NASDAQ:NRIX) reported $-0.76 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.8 by $0.04.
A. The conference call for Nurix Therapeutics, Inc.'s latest earnings report can be listened to online.
A. The conference call transcript for Nurix Therapeutics, Inc.'s latest earnings report can be read online.
A. Nurix Therapeutics, Inc. (NASDAQ:NRIX) has a recorded annual revenue of $76.99 M.
A. Nurix Therapeutics, Inc. (NASDAQ:NRIX) has a recorded net income of $76.99 M. Nurix Therapeutics, Inc. has generated $-2.65 earnings per share over the last four quarters.
A. Nurix Therapeutics, Inc. (NASDAQ:NRIX) has a price-to-earnings ratio of -7.51 and price/earnings-to-growth ratio is -0.2.
